An update on nonmelanoma skin cancer

Journal of Clinical and Aesthetic Dermatology

Volumn 4, Issue 2, 2011, Pages 20-27

  Patel, Rita V ^a   Frankel, Amylynne ^a   Goldenberg, Gary ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO N [4 CHLORO 3 (2 PYRIDINYL)PHENYL] 4 METHANESULFONYLBENZAMIDE; DICLOFENAC; FLUOROURACIL; IMIQUIMOD; INGENOL MEBUTATE; LIQUID NITROGEN; PROTEIN BCL 2; PROTEIN P53; RAPAMYCIN; SONIC HEDGEHOG PROTEIN;

ACTINIC KERATOSIS; ANTINEOPLASTIC ACTIVITY; APPLICATION SITE BURNING; APPLICATION SITE DRYNESS; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; APPLICATION SITE PAIN; BASAL CELL CARCINOMA; BURNING SENSATION; CANCER INHIBITION; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CREAM; CRYOSURGERY; CRYOTHERAPY; CURETTAGE; DRUG CLEARANCE; DRUG EFFICACY; GEL; GENE EXPRESSION; HEADACHE; HUMAN; HYPOPIGMENTATION; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; KAPOSI SARCOMA; LOSS OF FUNCTION MUTATION; MERKEL CELL TUMOR; OUTCOME ASSESSMENT; PAIN; PHOTODYNAMIC THERAPY; POLYOMA VIRUS; REVIEW; SKIN CANCER; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; TREATMENT DURATION;

EID: 79951656013     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Skin Cancer Facts. http://www.cancer.org/Cancer/CancerCauses/SunandUVExposure/skin-cancer-facts. Accessed on 04/30/2010.
2. Long CC, Marks R. Increased risk of skin cancer: another Celtic myth? A review of Celtic ancestry and other risk factors for malignant melanoma and nonmelanoma skin cancer. J Am Acad Dermatol. 1995;33(4):658-661.
3. Goldberg L. Review of actinic keratosis. Part 1: etiology, epidemiology and clinical presentation. J Drug Dermatol. 2010;9:1125-1132.
4. Stockfleth E, Ferrandiz C, Grob JJ, et al. Development of a treatment algorithm for actinic keratoses: a European consensus. Eur J Dermatol. 2008;18(6):651-659.
5. Anderson L, Schmieder GJ, Werschler WP, et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol. 2009;60(6): 934-943.
6. Siller G, Gebauer K, Welburn P, et al. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas J Dermatol. 2009;50(1):16-22.
7. Padilla RS, Sebastian S, Jiang Z, et al. Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression. Arch Dermatol. 2010;146:288-293.
8. Padilla RS, Sebastian S, Jiang Z, et al. Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression. Arch Dermatol. 2010;146:288-293.
9. Campione E, Diluvio L, Paternò EJ, Chimenti S. Topical treatment of actinic keratoses with piroxicam 1% gel: a preliminary open-label study utilizing a new clinical score. Am J Clin Dermatol. 2010;11(1):45-50.
10. Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer. 2009; 115(11):2523-2530.
11. Neidecker MV, Davis-Ajami ML, Balkrishnan R, et al. Pharmacoeconomic considerations in treating actinic keratosis. Pharmacoeconomics. 2009;27(6): 451-464.
12. Weinstock MA, Bingham SF, Cole GW, et al. Reliability of counting actinic keratoses before and after brief consensus discussion: the VA topical tretinoin chemoprevention (VATTC) trial. Arch Dermatol. 2001;137(8):1055-1058.
13. Weinstock MA, Lee KC, Chren MM, et al. Quality of life in the actinic neoplasia syndrome: The VA Topical Tretinoin Chemoprevention (VATTC) Trial. J Am Acad Dermatol. 2009;61(2):207-215.
14. Rowert-Huber J, Patel MJ, Forschner T, et al. Actinic keratosis is an early in-situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol. 2007;156(Suppl 3):8-12.
15. Silapunt S, Goldberg LH, Alam M. Topical and light-based treatments for actinic keratoses. Semin Cutan Med Surg. 2003;22(3):162-170.
16. Thai KE, Fergin P, Freeman M, et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol. 2004; 43(9):687-692.
17. Van der Geer S, Krekels GA. Treatment of actinic keratoses on the dorsum of the hands: ALA-PDT versus diclofenac 3% gel followed by ALA-PDT. A placebo-controlled, double-blind, pilot study. J Dermatolog Treat. 2009;20(5):259-265.
18. Stockfleth E, Meyer T, Benninghoff B, et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol. 2002;138(11):1498-1502.
19. Swanson N, Abramovits W, Berman B, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010;62(4):582-590.
20. Ogbourne SM, Suhrbier A, Jones B, et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res. 2004;64(8):2833-2839.
21. Challacombe JM, Suhrbier A, Parsons PG, et al. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol. 2006;177(11):8123-8132.
22. Hampson P, Kavanagh D, Smith E, et al. The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-delta dependent manner. Cancer Immunol Immunother. 2008;57(8):1241-1251.
23. Phase III study evaluating PEP005 (ingenol mebutate) Gel 0.05% to treat actinic keratosis (AK), a common pre-cursor to skin cancer. Presented at: the 68th Annual Meeting of the American Academy of Dermatology (AAD) (Scientific Session Poster Discussion: P105); March 5-9, 2010; Miami, FL. http://www.drugs.com/clinical_trials/phase-iii-region-study-shows-pep005-ingenol-mebutate-gel-0-05-may-reduce-pre-cancerous-skin-lesions-8944.html.
24. Moloney F, Vestergaard M, Radojkovic B, et al. Randomized, double-blinded, placebo controlled study to assess the effect of topical 1% nicotinamide on actinic keratoses. Br J Dermatol. 162(5):1138-1139.
25. Rubin AI, Chen EH, Ratner D. Basal cell carcinoma. N Engl J Med. 2005;353(21):2262-2269.
26. Kruger K, Blume-Peytavi U, Orfanos CE. Basal cell carcinoma possibly originates from the outer root sheath and/or the bulge region of the vellus hair follicle. Arch Dermatol Res. 1999;291(5):253-259.
27. Lo JS, Snow SN, Reizner GT, et al. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol. 1991;24(5 Pt 1):715-719.
28. Dessinioti C, Antoniou C, Katsambas A, et al. Basal cell carcinoma: what's new under the sun? Photochem Photobiol. 2010;86(3):481-491.
29. Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol. 2008;18(6):677-682.
30. Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol. 2008;18(5):547-553.
31. Siller G, Rosen R, Freeman M, et al. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas J Dermatol. 2010;51(2):99-105.
32. Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85(6):841-851.
33. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science. 1996;272(5268):1668-1671.
34. Xie J, Murone M, Luoh SM, et al. Activating Smoothened mutations in sporadic basal cell carcinoma. Nature. 1998;391(6662):90-92.
35. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal cell carcinoma. N Engl J Med. 2009;361(12): 1164-1172.
36. Fernandez EM, Helm T, Ioffreda M, et al. The vanishing biopsy: the trend toward smaller specimens. Cutis. 2005;76(5):335-339.
37. Tellechea O, Reis JP, Domingues JC, et al. Monoclonal antibody Ber EP4 distinguishes basal cell carcinoma from squamous cell carcinoma of the skin. Am J Dermatopathol. 1993;15(5):452-455.
38. Mitsuhashi T, Itoh T, Shimizu Y, et al. Squamous cell carcinoma of the skin: dual differentiations to rare basosquamous and spindle cell variants. J Cutan Pathol. 2006;33(3):246-252.
39. Beer TW, Shepherd P, Theaker JM. Ber EP4 and epithelial membrane antigen aid distinction of basal cell, squamous cell and basosquamous carcinomas of the skin. Histopathology. 2000;37(3):218-223.
40. Krahl D, Sellheyer K. Monoclonal antibody Ber-EP4 reliably discriminates between microcystic adnexal carcinoma and basal cell carcinoma. J Cutan Pathol. 2007;34(10):782-787.
41. Lansbury L, Leonardi-Bee J, Perkins W, et al. Interventions for non-metastatic squamous cell carcinoma of the skin. Cochrane Database Syst Rev. 2010(4):CD007869.
42. Cooper JZ, Brown MD. Special concern about squamous cell carcinoma of the scalp in organ transplant recipients. Arch Dermatol. 2006;142(6):755-758.
43. Brantsch KD, Meisner C, Schonfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008;9(8):713-720.
44. Penn I. Kaposi's sarcoma in organ transplant recipients: report of 20 cases. Transplantation. 1979;27(1):8-11.
45. Slavin G, Cameron HM, Singh H. Kaposi's sarcoma in mainland Tanzania: a report of 117 cases. Br J Cancer. 1969;23(2):349-357.
46. Taylor JF, Templeton AC, Vogel CL, et al. Kaposi's sarcoma in Uganda: a clinico-pathological study. Int J Cancer. 1971;8(1):122-135.
47. Antman K, Chang Y. Kaposi's sarcoma. N Engl J Med. 2000;342(14):1027-1038.
48. Montagnino G, Bencini PL, Tarantino A, et al. Clinical features and course of Kaposi's sarcoma in kidney transplant patients: report of 13 cases. Am J Nephrol. 1994;14(2): 121-126.
49. Haverkos HW, Drotman DP. Prevalence of Kaposi's sarcoma among patients with AIDS. N Engl J Med. 1985;312(23):1518.
50. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994;266(5192):1865-1869.
51. Godden-Kent D, Talbot SJ, Boshoff C, et al. Cyclin encoded by KS herpesvirus. Nature. 1996;382(6590):410.
52. Cheng EH, Nicholas J, Bellows DS, et al. A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. Proc Natl Acad Sci U S A. 1997;94(2):690-694.
53. Sodhi A, Montaner S, Patel V, et al. Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proc Natl Acad Sci U S A. 2004;101(14):4821-4826.
54. Masood R, Cai J, Zheng T, et al. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc Natl Acad Sci U S A. 1997;94(3): 979-984.
55. Dubina M, Goldenberg G. Viral-associated nonmelanoma skin cancers: a review. Am J Dermatopathol. 2009;31:561-573.
56. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med. 2005;352(13): 1317-1323.
57. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol. 2000;43(1 Pt 2):S6-S11.
58. Rybojad M, Borradori L, Verola O, et al. Non-AIDS-associated Kaposi's sarcoma (classical and endemic African types): treatment with low doses of recombinant interferon-alpha. J Invest Dermatol. 1990;95(6 Suppl):176S-179S.
59. Costa da Cunha CS, Lebbe C, Rybojad M, et al. Long-term follow-up of non-HIV Kaposi's sarcoma treated with low-dose recombinant interferon alfa-2b. Arch Dermatol. 1996;132(3):285-290.
60. Celestin Schartz NE, Chevret S, Paz C, et al. Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: a phase I to II, open-label trial in 17 patients. J Am Acad Dermatol. 2008;58(4):585-591.
61. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol. 2002;15(4):434-440.
62. Facchetti F, Lucini L, Gavazzoni R, et al. Immuno-morphological analysis of the role of blood vessel endothelium in the morphogenesis of cutaneous Kaposi's sarcoma: a study of 57 cases. Histopathology. 1988;12(6):581-593.
63. Weninger W, Partanen TA, Breiteneder-Geleff S, et al. Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest. 1999;79(2):243-251.
64. Folpe AL, Veikkola T, Valtola R, et al. Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas. Mod Pathol. 2000;13(2):180-185.
65. Dubina M, Goldenberg G. Positive staining of tumor-stage Kaposi's sarcoma with lymphatic marker D2-40. J Am Acad Dermatol. 2009;61(2):276-280.
66. Allen PJ, Bowne WB, Jaques DP, et al. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol. 2005;23(10):2300-2309.
67. Agelli M, Clegg LX. Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol. 2003;49(5):832-841.
68. Heath M, Jaimes N, Lemos B, et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol. 2008;58(3): 375-381.
69. Feng H, Shuda M, Chang Y, et al. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319(5866):1096-1100.
70. Mertz KD, Junt T, Schmid M, et al. Inflammatory monocytes are a reservoir for Merkel cell polyomavirus. J Invest Dermatol. 2010;130(4): 1146-1151.
71. Dworkin AM, Tseng SY, Allain DC, et al. Merkel cell polyomavirus in cutaneous squamous cell carcinoma of immunocompetent individuals. J Invest Dermatol. 2009;129(12):2868-2874.
72. Katano H, Ito H, Suzuki Y, et al. Detection of Merkel cell polyomavirus in Merkel cell carcinoma and Kaposi's sarcoma. J Med Virol. 2009;81(11):1951-1958.
73. Shah K, Nathanson N. Human exposure to SV40: review and comment. Am J Epidemiol. 1976;103(1):1-12.
74. Butel JS, Lednicky JA. Cell and molecular biology of simian virus 40: implications for human infections and disease. J Natl Cancer Inst. 1999;91(2):119-134.
75. Vilchez RA, Butel JS. Emergent human pathogen simian virus 40 and its role in cancer. Clin Microbiol Rev. 2004;17(3):495-508